23.00EUR-1.08%Mkt Cap: 925.71M EURP/E: 4.04Last update: 2026-06-01
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company deve…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap925.71M EUR
Enterprise Value568.25M EUR
Revenue (TTM)319.73M EUR
Gross Profit309.02M EUR
Net Income (TTM)229.68M EUR
Revenue/Share7.939 EUR
Last Price23.00 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees214
CountryIT
SectorHealthcare
IndustryBiotechnology
ISINIT0005373789
Valuation
P/E (Trailing)4.04
P/E (Forward)-57.74
PEG—
EV/EBITDA2.19
EV/Revenue1.78
P/S2.93
P/B7.44
EPS (TTM)5.70
EPS (Forward)-0.40
52W Range
19.5642% of range27.80
52W High27.80 EUR
52W Low19.56 EUR
Profitability
Gross Margin98.31%
Oper. Margin87.72%
EBITDA Margin81.35%
Profit Margin73.07%
ROE61.43%
ROA52.52%
Growth
Revenue Growth310.80%
Earnings Growth300.10%
Cash Flow & Leverage
Operating CF267.96M EUR
CapEx (TTM)3.63M EUR
FCF Margin63.04%
FCF Yield21.77%
Net Debt-368.30M EUR
Net Debt/EBITDA-1.42
Balance Sheet
Debt/Equity0.03
Current Ratio7.76
Quick Ratio7.69
Book Value/Sh3.125 EUR
Cash/Share9.414 EUR
Dividends
Fwd Div Rate0.7000 EUR
Trail. Div Rate0.7000 EUR
Div. Yield3.01%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)27.67 EUR
Target Range19.00 EUR – 34.00 EUR
# Analysts3
Ownership
Shares Out.28.88M
Float10.75M
Insiders62.15%
Institutions10.63%
Technical
SMA 5021.84 (+5.3%)
SMA 20022.59 (+1.8%)
Beta-0.02
S&P 52W Chg27.94%
Avg Vol (30d)17.68K
Avg Vol (10d)20.64K
Technical Indicators
RSI (14)63.1
MACD0.4769
MACD Signal0.3671
MACD Hist.+0.1098
BB Upper23.72 EUR
BB Middle22.39 EUR
BB Lower21.06 EUR
BB Width11.85%
ATR (14)0.7077 EUR
Vol Ratio (20d)0.41x